Forest Laboratories Launches Clinical Trial Registry

Forest Laboratories, an international pharmaceutical manufacturer and marketer, has posted its first set of data on the Forest Clinical Trial Registry.

The initial data posted includes results from all pediatric and adolescent studies for Forest's antidepressants Lexapro (escitalopram oxalate) and Celexa (citalopram hydrobromide), as well as information regarding ongoing clinical studies for Forest products under development.

Access to the registry is unrestricted and available at http://www.forestclinicaltrials.com (http://www.forestclinicaltrials.com) or through a link from the company's homepage http://www.frx.com (http://www.frx.com).